Neurocrine Biosciences Announces Phase 4 KINECT-PRO Data

Neurocrine Biosciences' Phase 4 KINECT-PRO study of INGREZZA capsules demonstrated significant improvements in patient-reported outcomes related to physical functioning, social interactions, and emotional well-being in tardive dyskinesia patients. The open-label study, which involved flexible dosing of INGREZZA (40-80mg), showed benefits across all severity levels of the condition. The company's stock is currently trading down 0.82% at $122.01.

Analysis

Neurocrine Biosciences (NBIX) announced positive data from its Phase 4 KINECT-PRO open-label study for INGREZZA capsules, specifically evaluating patient-reported outcomes in a tardive dyskinesia population reflective of real-world clinical practice. The study, which included a 24-week treatment period with flexible INGREZZA dosing (40 mg, 60 mg, or 80 mg once-daily after an initial four weeks at 40 mg), demonstrated robust and clinically meaningful improvements in patients' physical functioning, social interactions, and emotional well-being. Significantly, these positive outcomes were observed across all severity levels of tardive dyskinesia, highlighting INGREZZA's benefit even for individuals with milder uncontrolled movements who reported negative impacts at baseline. These findings, presented at the 2025 Psych Congress Elevate, reinforce the therapeutic value of INGREZZA in a broader patient context. Despite this encouraging clinical news, indicated by a "strongly positive" sentiment score of 0.65 and an NBIX-specific sentiment of 0.8, the company's stock is currently trading at $122.01, down 0.82 percent on the Nasdaq.

Key Decisions for Investors

• The positive Phase 4 KINECT-PRO data for INGREZZA, demonstrating broad improvements in patient-reported outcomes in real-world settings, strengthens the drug's clinical differentiation and may support continued market penetration and revenue growth for Neurocrine Biosciences.
• Investors should consider the favorable clinical results and high positive sentiment against the backdrop of the current minor stock decline of 0.82% to $122.01, evaluating if this presents a strategic opportunity given the enhanced value proposition of INGREZZA.
• Monitoring INGREZZA's upcoming sales figures and market share data will be crucial to assess the translation of these positive real-world efficacy findings into tangible financial performance for NBIX.